More than one million Americans experience heart attacks each year and that number is only getting bigger. Advances in science and diet are trying to find new ways to prevent heart attacks from happening. As the number two killer in America today, bigger steps need to be taken to save more lives.The Food and Drug Administration (FDA) recently approved AspirinWorks, a diagnostic test kit of human urine that aids in the qualitative detection of aspirin effect in apparently healthy individuals post ingestion.
“With more than one million Americans experiencing new or recurrent heart attacks each year, we believe AspirinWorks is important to the health of millions in the U.S., in addition to the rest of the world,” said Corgenix CFO Bill Critchfield in a statement.
Corgenix Medical Corporation (OTCBB: CONX) specializes in the healthcare field with its targeted focus on medical diagnostic products in the hemostasis, autoimmune, and vascular area. The company develops, manufactures and is involved in worldwide marketing for several products for the medical diagnostic industry.
After looking through the financials, Corgenix appears to be making positive growth in a few areas. Revenues grew by a little more than $1.1 million year over year, and gross profit grew at a faster rate last year than previously.
Depending on this last quarter that finished in June, Corgenix appears to be on pace to surpass last years’ totals in revenue and gross profit as well. Although they are tied up in their administrative costs, net profits in the last quarter experienced a 175 percent gain.
The price of stock for Corgenix is currently trading at $30 per share. Since May, the company has increased its stock price by 9 cents, or a gain of 42 percent. This increase could mean positive fourth quarter gains that could assist in the assumption the company will generate more revenues year over year again.
